Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 6/20 | 0.52 |
| ▸ | LTB4R2 | Q9NPC1 | 6/20 | 0.52 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.42 |
| ▸ | EDNRA | P25101 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | INSR | P06213 | 1/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23805215 | 0.84 | LTB4R (0.48) | LTB4RLTB4R2PLA2G2ACNR2EDNRA | |
| SCHEMBL12558840 | 0.76 | HTR2A (0.57) | LTB4RLTB4R2EDNRAPTGER1ABCG2 | |
| SCHEMBL24499146 | 0.74 | LTB4R (0.42) | LTB4RLTB4R2PLA2G2APTGER1 | |
| SCHEMBL29832165 | 0.74 | LTB4R (0.42) | LTB4RLTB4R2PLA2G2APTGER1 | |
| SCHEMBL31708184 | 0.74 | LTB4R (0.40) | LTB4RLTB4R2CNR2LMNAPTGER1 | |
| SCHEMBL15323678 | 0.74 | LTB4R (0.63) | LTB4RLTB4R2ALKLMNAINSR | |
| SCHEMBL15323681 | 0.74 | LTB4R (0.63) | LTB4RLTB4R2ALKLMNAINSR | |
| SCHEMBL3048085 | 0.73 | ALK (0.54) | LTB4RLTB4R2ALKEDNRAINSR | |
| SCHEMBL12558831 | 0.73 | HTR2C (0.61) | LTB4RLTB4R2ABCG2MAPTMAPK1 | |
| SCHEMBL25606378 | 0.72 | LTB4R (0.41) | LTB4RLTB4R2PLA2G2ACNR2EDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230140635-A1 | 3-(2-(Aminoethyl)-Indol-4-ol Derivatives, Methods of Preparation Thereof, and the Use as 5-HT2 Receptor Modulators | BRIGHT MINDS BIOSCIENCES INC. (CA) | 2023-05-04 | — | — | US | disclosed |
| WO-2021179091-A1 | 3-(2-(AMINOETHYL)-INDOL-4-OL DERIVATIVES, METHODS OF PREPARATION THEREOF, AND THE USE AS 5-HT2 RECEPTOR MODULATORS | BRIGHT MINDS BIOSCIENCES INC. (CA) | 2021-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140635-A1 | 3-(2-(Aminoethyl)-Indol-4-ol Derivatives, Methods of Preparation Thereof, and the Use as 5-HT2 Receptor Modulators | HTR2C, HTR2A, HTR2B | LTB4R 88/4885LTB4R2 40/4885PLA2G2A 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.